Abstract: HepatologyVolume 33, Issue 1 p. 301-307 Clinical ChallengeFree Access Hepatic osteodystrophy Smita Rouillard, Smita Rouillard University of California San Francisco at Fresno, Fresno, CASearch for more papers by this authorNancy E. Lane M.D.,, Corresponding Author Nancy E. Lane M.D., [email protected] University of California San Francisco, San Francisco, CADivision of Rheumatology, Box 0868, UCSF, San Francisco, CA 94143. fax: 415-648-8425.===Search for more papers by this author Smita Rouillard, Smita Rouillard University of California San Francisco at Fresno, Fresno, CASearch for more papers by this authorNancy E. Lane M.D.,, Corresponding Author Nancy E. Lane M.D., [email protected] University of California San Francisco, San Francisco, CADivision of Rheumatology, Box 0868, UCSF, San Francisco, CA 94143. fax: 415-648-8425.===Search for more papers by this author First published: 30 December 2003 https://doi.org/10.1053/jhep.2001.20533Citations: 92AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Diamond TH, Stiel D, Lunzer M, McDowall D, Eckstein RP, Posen S. Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease. Gastroenterology 1989; 96: 213–221.MEDLINE 10.1016/0016-5085(89)90783-X CASPubMedWeb of Science®Google Scholar 2 Matloff DS, Kaplan MM, Neer RM, Goldberg MT, Bitman W, Wolfe HJ. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D treatment. Gastroenterology 1982; 83: 97–102.MEDLINE PubMedWeb of Science®Google Scholar 3 Herlong HF, Recker RR, Maddrey WC. Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology 1982; 83: 103–108.MEDLINE 10.1016/S0016-5085(82)80292-8 CASPubMedWeb of Science®Google Scholar 4 Cuthbert JA, Pak CYC, Zerwekh JE, Glass KD, Combes B. Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia. Hepatology 1984; 4: 1–8.MEDLINE 10.1002/hep.1840040101 PubMedWeb of Science®Google Scholar 5 Stellon AJ, Webb A, Compston JE. Bone histomorphometry and structure in corticosteroid-treated chronic active hepatitis. Gut 1988; 29: 378–384.MEDLINE 10.1136/gut.29.3.378 PubMedWeb of Science®Google Scholar 6 Lalor BC, France MW, Powell D, Adams PH, Counichan TB. Bone and mineral metabolism and chronic alcohol abuse. QJ Med 1986; 59: 497–511. PubMedWeb of Science®Google Scholar 7 Heaney RP. The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 1194; 9: 1515–1523. Google Scholar 8 McCaughan GW, Feller RB. Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management. Dig Dis 1994; 12: 223–231.MEDLINE 10.1159/000171456 CASPubMedWeb of Science®Google Scholar 9 Eriksen EF, Kassem M, Langdahl B. Growth hormone, insulin-like growth factors and bone remodeling. Eur J Clin Invest 1996; 26: 525–534.MEDLINE 10.1046/j.1365-2362.1996.00292.x CASPubMedWeb of Science®Google Scholar 10 Slootweg MC, Hoogerbrugge CM, de Poorter TL, Duursma SA, Van Buul Offers SC. The presence of classical insulin-like growth factor (IGF) type-I and -II receptors on mouse osteoblasts: autocrine/paracrine growth effects of IGF's? J Endocrinol 1990; 125: 271–277.MEDLINE 10.1677/joe.0.1250271 CASPubMedWeb of Science®Google Scholar 11 Cemborain A, Castilla-Cortazar I, Garcia M, Quiroga J, Muguerza B, Picardi A, Santidrian S, Prieto J. Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. J Hepatol 1998; 28: 122–131.MEDLINE 10.1016/S0168-8278(98)80211-0 CASPubMedWeb of Science®Google Scholar 12 Schimpf RM, Lebrec D, Donadieu M. Somatomedin production in normal adults and cirrhotic patients. Acta Endocrinol 1977; 86: 355–362.MEDLINE PubMedWeb of Science®Google Scholar 13 Hattori N, Urahachi H, Ikekubo K, Ishihara T, Moridera K, Hino M. Serum growth hormone-binding protein, insulin-like growth factor-1 and growth hormone in patients with liver cirrhosis. Metab Clin Exp 1992; 41: 377–381.MEDLINE 10.1016/0026-0495(92)90071-H CASPubMedWeb of Science®Google Scholar 14 Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998; 28: 695–699.MEDLINE 10.1002/hep.510280315 CASPubMedWeb of Science®Google Scholar 15 Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995; 95: 2581–2586.MEDLINE 10.1172/JCI117959 CASPubMedWeb of Science®Google Scholar 16 Bell H, Raknerud N, Falch JA, Haug E. Inappropriately low levels of gonadotrophins in amenorrhoeic women with alcoholic and non-alcoholic cirrhosis. Eur J Endocrinol 1995; 132: 444–449.MEDLINE 10.1530/eje.0.1320444 CASPubMedWeb of Science®Google Scholar 17 Bagur A, Mautalen C, Findor J, Sorda J, Somoza J. Risk factors for the development of vertebral and total skeleton osteoporosis in patients with primary biliary cirrhosis. Calcif Tissue Int 1998; 63: 385–390.MEDLINE 10.1007/s002239900545 CASPubMedWeb of Science®Google Scholar 18 Pignata S, Daniele B, Galati MG, Esposito G, Vallone P, Fiore F, Ricchi P, et al. Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma. Eur J Gastroenterol Hepatol 1997; 9: 283–286.MEDLINE 10.1097/00042737-199703000-00012 CASPubMedWeb of Science®Google Scholar 19 Chappard D, Plantard B, Fraisse H, Palle S, Alexandre C, Riffat G. Bone changes in alcoholic cirrhosis of the liver. A histomorphometric study. Pathol Res Pract 1989; 18: 480–485. 10.1016/S0344-0338(89)80138-4 Google Scholar 20 Baran DT, Teitelbaum SL, Bergfeld MA. Effects of alcohol ingestion on bone and mineral metabolism in rats. Am J Physiol 1980; 238: 507–510. CASPubMedWeb of Science®Google Scholar 21 Hay JE. Bone disease in cholestatic liver disease. Gastroenterology 1995; 108: 276–283.MEDLINE 10.1016/0016-5085(95)90033-0 PubMedWeb of Science®Google Scholar 22 Arnaud SB. Editorial: 25-Hydroxyvitamin D treatment of bone disease in primary biliary cirrhosis. Gastroenterology 1982; 83: 137–149.MEDLINE PubMedWeb of Science®Google Scholar 23 Hay JE, Lindor KD, Weisner RH, Dickson ER, Krom RAF, LaRusso LF. The metabolic bone disease of primary sclerosing cholangitis. Hepatology 1991; 14: 257–261.MEDLINE 10.1002/hep.1840140209 PubMedWeb of Science®Google Scholar 24 Hodgson SF, Dickson ER, Wahner HW, Johnson KA, Mann KG, Riggs BL. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 1985; 103: 855–860.MEDLINE 10.7326/0003-4819-103-6-855 PubMedWeb of Science®Google Scholar 25 Morrison NA, Qi JC, Tokita A, Kelly P, Crofts L, Nguyen TV, Sambrook PN, et al. Prediction of bone mineral density from vitamin D receptor alleles. Nature 1994; 367: 284–287.MEDLINE 10.1038/367284a0 CASPubMedWeb of Science®Google Scholar 26 Cooper GS, Umbach DM. Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis. J Bone Miner Res 1996; 12: 1841–1849. Google Scholar 27 Dawson-Hughes B, Harris S, Finnerman S. Calcium absorption on high and low calcium intake in relation to vitamin D receptor genotype. J Clin Endocrinol Metab 1995; 80: 3657–3661.MEDLINE 10.1210/jc.80.12.3657 CASPubMedWeb of Science®Google Scholar 28 Gennari L, Becherini L, Masi L, Gonnelli S, Cepollaro C, Martini S, Mansani R, et al. Vitamin D receptor genotypes and intestinal calcium absorption in postmenopausal women. Calicif Tissue Int 1997; 61: 460–463. 10.1007/s002239900368 CASPubMedWeb of Science®Google Scholar 29 Howard H, Nguyen T, Morrison N, Watanabe T, Sambrook P, Eisman J, Kelly PJ. Genetic influences on bone mineral density: physiological correlates of vitamin D receptor alleles in premenopausal women. J Clin Endocrinol Metab 1995; 80: 2800–2805.MEDLINE 10.1210/jc.80.9.2800 CASPubMedWeb of Science®Google Scholar 30 Porayko MK, Weisner RH, Hay JE, Krom RAF, Dickson ER, Beaver S, Schwerman L. Bone disease in liver transplant recipients: incidence, timeing and risk factors. Transplant Proc 1991; 23: 1462–1465.MEDLINE PubMedWeb of Science®Google Scholar 31 Hodgson SF, Dickson ER, Eastell R, Erikson EF, Bryant SC, Riggs BL. Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. Bone 1993; 14: 819–827.MEDLINE 10.1016/8756-3282(93)90310-7 PubMedWeb of Science®Google Scholar 32 Mitchinson HC, Malcolm AJ, Bassendine MF, James OFW. Metabolic bone disease in primary biliary cirrhosis at presentation. Gastroenterology 1988; 94: 463–470.MEDLINE PubMedWeb of Science®Google Scholar 33 Guanabens N, Pares AML, Brancos A, Piera C, Serrano S, Rivera F, Rodes J. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990; 85: 1356–1362.MEDLINE PubMedWeb of Science®Google Scholar 34 Crippin JS, Jorgensen RA, Dickson ER, Lindor KD. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 1994; 89: 47–50.MEDLINE PubMedWeb of Science®Google Scholar 35 Springer JE, Cole DEC, Rubin LA, Cauch-Dudek K, Harewod L, Evrovski J, Peltekova VD, et al. Vitamin-D receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000; 118: 145–151.MEDLINE 10.1016/S0016-5085(00)70423-9 CASPubMedWeb of Science®Google Scholar 36 Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309–319.MEDLINE 10.1016/S0092-8674(00)80209-3 CASPubMedWeb of Science®Google Scholar 37 Adler RA, Rosen CJ. Glucocorticoids and osteoporosis. Endocrinol Metab Clin 1994; 23: 641–654. PubMedWeb of Science®Google Scholar 38 Hay JE. Bone disease in liver transplant recipients. Gastroenterol Clin North Am 1993; 22: 337–349.MEDLINE CASPubMedWeb of Science®Google Scholar 39 Feller RB, McDonald JA, Sherbon KJ, McCaughan GW. Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. Liver Transpl Surg 1999; 5: 407–413.MEDLINE 10.1002/lt.500050507 CASPubMedWeb of Science®Google Scholar 40 McDonald JA, Dunstan CR, Dilworth P, Sherbon K, Ross Sheil AG, Evans RA, McCaughan GW. Bone loss after liver transplantation. Hepatology 1991; 14: 613–619.MEDLINE 10.1002/hep.1840140407 CASPubMedWeb of Science®Google Scholar 41 Schlosberg M, Movsowitz C, Epstein S. The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology 1989; 124: 2179–2184.MEDLINE 10.1210/endo-124-5-2179 CASPubMedWeb of Science®Google Scholar 42 Cvetkovic M, Mann G, Romero D. Deleterious effects of longterm cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 1194; 57: 1231–1237. Google Scholar 43 Bowman AR, Dass DA, Dissanayake IR. The role of testosterone in cyclosporin-induced osteopenia. J Bone Miner Res 1997; 12: 607–615.MEDLINE 10.1359/jbmr.1997.12.4.607 CASPubMedWeb of Science®Google Scholar 44 Miller PD, Bonnick SL, Rosen C. Guidelines for the clinical utilization of bone mass measurement in the adult population. Calcif Tissue Int 1995; 57: 251–252.MEDLINE 10.1007/BF00298878 CASPubMedWeb of Science®Google Scholar 45 Lai D, Rencken M, Drinkwater B, Chestnut CH. Site of bone density measurement may affect therapy decision. Calcif Tissue Int 1993; 53: 225–228.MEDLINE 10.1007/BF01320905 CASPubMedWeb of Science®Google Scholar 46 Diamond T, Stiel D, Lunzer M, Wilkinson M, Roche J, Posen S. Osteoporosis and skeletal fractures in chronic liver disease. Gut 1990; 31: 82–87.MEDLINE 10.1136/gut.31.1.82 PubMedWeb of Science®Google Scholar 47 Meys E, Fontanges E, Fourcade N, Thomasson A, Pouyet M, Delmas PD. Bone loss after orthotopic liver transplantation. Am J Med 1994; 97: 445–450.MEDLINE 10.1016/0002-9343(94)90324-7 CASPubMedWeb of Science®Google Scholar 48 Sheth P. Osteoporosis and exercise. Mt Sinai J Med 1999; 66: 197–200.MEDLINE CASPubMedWeb of Science®Google Scholar 49 Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 1996; 125: 961–968.MEDLINE 10.7326/0003-4819-125-12-199612150-00004 CASPubMedWeb of Science®Google Scholar 50 Camisasca M, Crosignani A, Battezzati PM, Albisetti W, Grandinetti G, Pietrogrande L, Biffi A, et al. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 1994; 20: 633–637.MEDLINE 10.1016/0270-9139(94)90098-1 PubMedWeb of Science®Google Scholar 51 NIH Consensus Development Panel. JAMA 1994; 272: 1942–1948.MEDLINE CASPubMedWeb of Science®Google Scholar 52 Reed JS, Meredith SC, Nemchausky BA. Bone disease in primary biliary cirrhosis: reversal of osteomalacia with oral 25-hydroxyvitamin D. Gastroenterology 1980; 78: 513–517. Google Scholar 53 Mobarhan SA, Russell RM, Recker RR, Posner DB, Iber FL, Miller P. Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D, 25-hydroxyvitamin D, or supportive treatment. Hepatology 1984; 4: 266–273.MEDLINE 10.1002/hep.1840040216 CASPubMedWeb of Science®Google Scholar 54 Shiomi S, Masaki K, Habu D, Takeda T, Nishiguchi S, Kuroki T, Ochi H. Calcitriol for bone loss in patients with primary biliary cirrhosis. J Gastroenterol 1999; 34: 241–245.MEDLINE 10.1007/s005350050250 CASPubMedWeb of Science®Google Scholar 55 Shiomi S, Masaki K, Habu D, Takeda T, Nishiguchi S, Kuroki T, Ochi H. Calcitriol for bone disease in patients with cirrhosis of the liver. J Gastroenterol Hepatol 1999; 14:6: 547–552. 10.1046/j.1440-1746.1999.01913.x CASPubMedWeb of Science®Google Scholar 56 Diamond TH, Stiel D, Posen S. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemachromatosis. J Bone Miner Res 1991; 6: 39–43.MEDLINE 10.1002/jbmr.5650060108 PubMedWeb of Science®Google Scholar 57 Schreiber AJ, Simon FR. Estrogen-induced cholestasis: clues to pathogenesis and treatment. Hepatology 1983; 3: 607–613.MEDLINE 10.1002/hep.1840030422 CASPubMedWeb of Science®Google Scholar 58 Clements D, Rhodes J. Hormone replacement therapy in chronic active hepatitis: a case report. Gut 1993; 34: 1639–1640.MEDLINE 10.1136/gut.34.11.1639 CASPubMedWeb of Science®Google Scholar 59 Olsson R, Mattson LA, Obrant K, Mellstrom D. Estrogen-progesterone therapy for low bone mineral density in primary biliary cirrhosis. Liver 1999; 19: 188–192.MEDLINE 10.1111/j.1478-3231.1999.tb00034.x CASPubMedWeb of Science®Google Scholar 60 Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992; 7: 1063–1069.MEDLINE 10.1002/jbmr.5650070909 CASPubMedWeb of Science®Google Scholar 61 Koffe I, Katz I, Jacobs T. 17-Beta-Estradiol prevents osteopenia in oophorectomized rats treated with cyclosporin-A. Endocrinology 1992; 130: 1578–1586.MEDLINE 10.1210/en.130.3.1578 PubMedWeb of Science®Google Scholar 62 Chesnut C, Silverman SL, Andriano K, Genant H, Gimona A, Harris S, et al. Salmon calcitonin nasal spray (NS-CT) reduces risk of vertebral fracture(s) (VF) in established osteoporosis and has continuous efficacy with prolonged treatment: accrued 5 year worldwide data of the PROOF study. Am J Med 2000; 109: 267–274.MEDLINE 10.1016/S0002-9343(00)00490-3 CASPubMedWeb of Science®Google Scholar 63 Overgaard K, Hansen M. Effects of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis. Br Med J 1992; 305: 556–561. 10.1136/bmj.305.6853.556 CASPubMedWeb of Science®Google Scholar 64 Lyritis GP, Isakalakos S, Magiasis B. Analgesic effect of calcitonin in osteoporotic vertebral fractures. A double-blind placebo controlled study. Cal Tiss Int 1991; 49: 369. 10.1007/BF02555844 CASPubMedWeb of Science®Google Scholar 65 Floreani A, Zappala F, Fries W, Naccarato R, Plebani M, D'Angelo A, Chiaramonte M. A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J Clin Gastroenterol 1997; 24: 239–244.MEDLINE 10.1097/00004836-199706000-00012 CASPubMedWeb of Science®Google Scholar 66 Sambrook P, Birmingham J, Kelly P, Kempler S. Prevention of corticosteroid osteoporosis. N Engl J Med 1993; 328: 1747–1752.MEDLINE 10.1056/NEJM199306173282404 CASPubMedWeb of Science®Google Scholar 67 Stein B, Takizawa M, Katz I, Berlin J, Joffe I, Fallon M, Epstein S. Salmon calcitonin prevents cyclosporin A induced high turnover bone loss. Endocrinology 1991; 129: 92–98.MEDLINE 10.1210/endo-129-1-92 CASPubMedWeb of Science®Google Scholar 68 Valero MA, Loinaz C, Larrodera L, Leon M, Moreno E, Hawkins F. Calcitonin and bisphophonates treatment in bone loss after liver transplantation. Calcif Tissue Int 1995; 57: 15–19.MEDLINE 10.1007/BF00298990 CASPubMedWeb of Science®Google Scholar 69 Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 22: 1437–1443. 10.1056/NEJM199511303332201 Web of Science®Google Scholar 70 Harris S, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chestnut CH, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group. JAMA 1999; 282: 1344–1352.MEDLINE 10.1001/jama.282.14.1344 CASPubMedWeb of Science®Google Scholar 71 Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, et al. Intermittant etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337: 382–387.MEDLINE 10.1056/NEJM199708073370603 CASPubMedWeb of Science®Google Scholar 72 Diamond TH, McGuigan L, Barbagallo S, Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 1995; 98: 459–463.MEDLINE 10.1016/S0002-9343(99)80345-3 CASPubMedWeb of Science®Google Scholar 73 Saag K, Emkey R, Schnitzer T, Brown JP, Hawkins F, Goemaere S, Thamsborg G, et al. Alendronate for the prevention of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339: 292–299.MEDLINE 10.1056/NEJM199807303390502 CASPubMedWeb of Science®Google Scholar 74 Cohen S, Levy RM, Keller M. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve month multicenter randomized double-blind, placebo-controlled parallel group study. Arthritis Rheum 1999; 42: 2309–2318.MEDLINE 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K CASPubMedWeb of Science®Google Scholar 75 Wolfhagen FH, van Buuren HR, den Ouden JW, Hop WC, van Leeuwen JP, Schalm SW, Pols HA. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. J Hepatol 1997; 26: 325–330.MEDLINE 10.1016/S0168-8278(97)80048-7 CASPubMedWeb of Science®Google Scholar 76 Reeves HL, Francis RM, Manas DM, Hudson M, Day CP. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 1998; 4: 404–409.MEDLINE 10.1002/lt.500040508 CASPubMedWeb of Science®Google Scholar 77 Lindsay R. Editorial: fluoride and bone—quantity versus quality. N Engl J Med 1990; 322: 845–846.MEDLINE 10.1056/NEJM199003223221210 CASPubMedWeb of Science®Google Scholar 78 Meunier PJ, Brancon D, Chavassieux P. Treatment with fluoride. In: C Christiansen, JS Johansen, BJ Riis, eds. Osteoporosis. Copenhagen: Osteopress 1987; 824–828. Google Scholar 79 Riggs BL, Hodgson SF, O'Fallon WM, Chao EYS, Wahner HW, Muhs JM, Cedel SL, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 802–809.MEDLINE 10.1056/NEJM199003223221203 CASPubMedWeb of Science®Google Scholar 80 Pak CYC, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Pointdexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med 1995; 123: 401–408.MEDLINE 10.7326/0003-4819-123-6-199509150-00001 CASPubMedWeb of Science®Google Scholar 81 Guanabens N, Pares A, del Rio L, Roca M, Gomez R, Munoz J, Rodes J. Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol 1992; 15: 345–349.MEDLINE 10.1016/0168-8278(92)90066-X PubMedWeb of Science®Google Scholar 82 Neuhaus R, Lohmann R, Platz KP, Guckelberger O, Schon M, Lang M, Hierholzer J, et al. Treatment of osteoporosis after liver transplantation. Transplant Proc 1995; 27: 1226–1227.MEDLINE CASPubMedWeb of Science®Google Scholar 83 Lindor KD, Janes Ch, Crippin JS. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology 1995; 21: 389–392.MEDLINE 10.1002/hep.1840210219 CASPubMedWeb of Science®Google Scholar 84 Kurihara N, Roodman GD. Interferon alpha and gamma inhibit interleukin 1 beta-stimulated osteoclast-like cell formation in long-term human marrow cultures. J Interferon Res 1990; 10: 541–547.MEDLINE 10.1089/jir.1990.10.541 CASPubMedWeb of Science®Google Scholar 85 Miki T, Yoshida H, Shioi A. Effect of interferon alpha on bone metabolism in patients with chronic hepatitis. J Bone Miner Metab 1993; 11: 39–44. 10.1007/BF02383532 Google Scholar 86 Epstein S, Shane E, Bilezikian JP. Organ transplantation and osteoporosis. Current Opinion Rheum 1995; 7: 255–261. 10.1097/00002281-199505000-00018 PubMedGoogle Scholar Citing Literature Volume33, Issue1January 2001Pages 301-307 ReferencesRelatedInformation